Target
Gemcitabine
142 abstracts
Abstract
Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial.Org: Sun Yat-sen University Cancer Center, Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Centre, Department of Oncology, National Taiwan University Hospital, Affiliated Hospital of Guizhou Medical University,
Abstract
Clonal hematopoiesis of indeterminate potential (CHIP): Outcomes and adverse events in patients with solid tumors.Org: Pancreas Centre BC, Department of Pathology & Laboratory Medicine Vancouver General Hospital, British Columbia Cancer Research Centre, Providence Health - St. Paul's Hospital,
Abstract
Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study.Org: Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, Jiangsu Province Hospital, Nanjing, China, Hunan Cancer Hospital, Changsha, China, Shandong Cancer Hospital and Institute, Jinan, China, Zhejiang Cancer Hospital, Hangzhou, China,
Abstract
Ipatasertib (IPA) combined with non-taxane chemotherapy (CT) for patients (pts) with previously treated advanced triple-negative breast cancer (aTNBC): The PATHFINDER phase IIa trial.Org: Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas&Co, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Hospital Universitario Ramón y Cajal,
Abstract
Evaluation of the study of control arms in randomized clinical trials of cancer.Org: Brown University School of Medicine-Rhode Island Hospital, Memorial Sloan Kettering Cancer Center, Yale University School of Medicine, Saint Louis University School of Medicine, UNC Lineberger Comprehensive Cancer Center,
Abstract
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).Org: Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Université Paris-Sud, Université Paris-Saclay, Netherlands Cancer Institute,
Abstract
Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.Org: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, Barts Cancer Institute,
Abstract
A phase 1 study of liposomal irinotecan in patients with advanced breast cancer.Org: Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Harbin Medical University Cancer Hospital, Harbin, China, Department of Breast, Henan Cancer Hospital, Zhengzhou, China, Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China,
Abstract
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.Org: Fox Chase Cancer Center, Dana-Farber Cancer Institute, Wake Forest University Department of General Internal Medicine, Stanford University School of Medicine, ThedaCare Regional Medical Center,
Abstract
A phase 2a safety run-in and preliminary efficacy study of liposomal gemcitabine (FF-10832) in combination with pembrolizumab in patients with advanced solid tumors.Org: Atlantic Hematology Oncology, Morristown Medical Center, Morristown, NJ, FUJIFILM Pharmaceuticals USA, FUJIFILM Corporation,
Abstract
SOGUG-Vexillum: Phase II non-randomized clinical trial of nivolumab/ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer.Org: Toledo, Spain, Santiago De Compostela, Spain, Sevilla, Spain, Oviedo, Spain, Huelva, Spain,
Abstract
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3.Org: Florida Cancer Specialists North Division, Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron University Hospital and Vall d'Hebrón Institute of Oncology (VHIO), IPSEN Bioinnovation Limited, Università degli studi di Verona and Azienda Ospedaliera Universitaria Integrata,
Abstract
Three-year follow-up data from KEYNOTE-966: Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC).Org: Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Prince of Wales Hospital, Department of Clinical Oncology, The Chinese University of Hong Kong, Amsterdam UMC, University of Amsterdam, Department of Medical Oncology, ENETS Center of Excellence, Cancer Center Amsterdam, Gastroenterology, Hepatology, Infectious Diseases and Endocrinology Department, Hannover Medical School,
Abstract
Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase 3 trial.Org: Fujian Province Cancer Hospital, Department of Radiation Oncology, Jiangxi Cancer Hospital, Department of Radiation Oncology, Fudan University Shanghai Cancer Center,
Abstract
Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).Org: Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Centre, Guangzhou, China, Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China, Department of Radiation Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, guangzhou, China, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China, Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, China,
Abstract
Interim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer.Org: Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron University Hospital and Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, Spain, Yale University School of Medicine, New Haven, CT, Sheba Medical Center, Ramat Gan, and Tel Aviv University, Tel Aviv, Israel, Rambam Medical Center, Haifa, Israel, HonorHealth Research Institute, Scottsdale, AZ,
Abstract
Phase 1 study of anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody MK-0482 + pembrolizumab + gemcitabine + nab-paclitaxel (Gem/Nab-P) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).Org: Ramat Gan, Hadassah Hebrew - University Medical Center, Jerusalem, Medical Oncology and Immunotherapy, Siena,
Abstract
Real-world data comparison of time to next treatment for patients with HER2 low metastatic treated with either chemotherapy or fam-trastuzumab deruxtecan-nxki following chemotherapy in the metastatic setting.Org: University of Pittsburgh Medical Center (UPMC), Integra Connect PrecisionQ, Highlands Oncology Group, South Carolina Oncology Associates, Integra Connect,
Abstract
GEMINI-Hepatobiliary: A phase 2 study of novel first-line immuno-oncology-based treatments in patients with advanced hepatobiliary cancers.Org: NTUH Cancer Hospital, B2F Samsung Comprehensive Cancer Center, Jiangsu, China, Shatin, Hong Kong,
Abstract
Overall survival outcomes of phase II GECCOR-GB trial, a multicentre trial of adjuvant adjuvant gemcitabine plus cisplatin (GC) and capecitabine with concurrent capecitabine radiotherapy (Cape-RT) for operated gallbladder cancer (GBC).Org: Mahamana Pandit Madan Mohan Malviya Cancer Centre, Homi Bhabha Cancer Hospital & Research Centre,
Abstract
Novel organoid platform for drug screening of patients with breast cancer.Org: Cellentia, Acrocyte Therapeutics Inc., New Taipei City, Taiwan,
Abstract
A phase III randomized trial of eribulin (E) with gemcitabine (G) vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 updated design.Org: Davis Comprehensive Cancer Center, Swog Gu Bladder Patient Advocate,
Abstract
Phase II study of pirfenidone combined with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer.Org: Department of Pancreatobiliary Surgery,
Abstract
CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors.Org: Global Medicines Development,
Abstract
Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301.Org: Broward Health, Genmab US, Inc.,
Abstract
A phase 2/3 study of Bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC): Duravelo-2.Org: University Paris Saclay,
Abstract
Results of a randomized phase II trial of 2nd-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib: Japan Clinical Oncology Group study JCOG1802 (2ND-STEP).Org: Fukui University School of Medicine,
Abstract
VIRAGE: A phase IIb, open-label, randomized study of nab-paclitaxel and gemcitabine plus/minus VCN-01 in patients with metastatic pancreatic cancer.Org: Vall d´Hebrón Institute of Oncology (VHIO),
Abstract
A randomised phase 2 study of liposomal irinotecan in combination with 5-fluorouracil/leucovorin and oxalipalatin versus nab-paclitaxel plus gemcitabine in unresectable locally advanced or metastatic pancreatic cancer.Org: Liaoning Cancer Hospital, Shenyang, China, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Yunnan Cancer Hospital, Yunnan, China, CSPC Ouyi Pharmaceutical Technology (Shijiazhuang) Co.,Ltd, Shijiazhuang, China,
Abstract
Impact of hepatitis B virus (HBV) infection on efficacy and safety in the KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC).Org: Amsterdam UMC, University of Amsterdam, ENETS Center of Excellence, Cancer Center Amsterdam, Charite Campus Charite Mitte,
Abstract
Phase II study of neoadjuvant durvalumab and tremelimumab in combination with gemcitabine and cisplatin in patients with intrahepatic cholangiocarcinoma that is borderline resectable or resectable with high risk for recurrence.Org: Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, MedStar Health,
Abstract
Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multicenter, open-label, single-arm, phase II study.Org: The Cancer Center of the Fifth Affiliated Hospital, The First People's Hospital of Zhaoqing, Jiangmen Central Hospital, Zhuhai Maternity and Child Health Hospital, Zhuhai Hospital of lntegrated Traditional Chinese and Western Medicine,
Abstract
A phase II clinical trial of toripalimab combined with cisplatin plus gemcitabine chemotherapy as neoadjuvant treatment for muscle-invasive bladder cancer.Org: Affiliated Hospital of Medical School, Nanjing University,
Abstract
Safety and efficacy of iparomlimab and tuvonralimab in combination with gemcitabine and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase 2 trial (DUBHE-N-302).Org: Qilu Pharmaceutical, Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, China, Sun Yat-sen University Cancer Center Gansu Hospital,
Abstract
Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.Org: The Affiliated Cancer Hospital of Guangxi Medical University, First Affiliated Hospital of Guangxi Medical University, First People’s Hospital of Yulin City,
Abstract
Clinical and translational results from REVOLUTION cohorts A (nivolumab + ipilimumab + chemotherapy) and B (hydroxychloroquine + ipilimumab + chemotherapy) in patients with previously untreated metastatic pancreatic adenocarcinoma.Org: 1440 Foundation,
Abstract
P-GEMOX with sequential or sandwiched radiotherapy for early-stage extranodal natural killer/T-cell lymphoma.Org: The First Affiliated Hospital - Zhejiang University School of Medical, Hangzhou, China, Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, The First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China,
Abstract
Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of cisplatin (cis)-eligible population from EV-302/KEYNOTE-A39.Org: Barts Cancer Centre, QMUL, London, United Kingdom, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, New York, NY, Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent and Center for Oncological Research (CORE), Integrated Personalised and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium, Charing Cross Hospital, London, United Kingdom, University of California, Los Angeles Medical Center, Los Angeles, CA,
Abstract
Efficacy and safety of luveltamab tazevibulin vs investigator’s choice of chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC) expressing folate receptor alpha (FRα): The REFRaME-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study.Org: Medical Oncology Service, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain, Yonsei Cancer Center and Severance Hospital, Seoul, South Korea, Department of Gynaecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, The Royal Hospital for Women, Sydney, Australia, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA,
Abstract
A phase Ia, dose-escalation study of IMB071703 injection in patients (pts) with recurrent or metastatic, advanced solid tumors.Org: Shanghai East Hospital, Tongji University, Shanghai, China, School of Medicine, Zhejiang University, Hangzhou, China, Tongji University School of Medicine, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Induction chemotherapy followed by concurrent chemoradiotherapy combined with toripalimab and Endostar in high-risk locally advanced nasopharyngeal carcinoma: A multicenter, randomized, phase 2 trial.Org: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Department of Radiation Oncology, The Second Affiliated Hospital of Guangxi University of Science and Technology, Liuzhou, China,
Abstract
Prediction of therapeutic response and cancer outcomes in solid tumours via in silico clinical trials.Org: Concr LTD, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow,
Abstract
Benchmarking the transcriptomic predictive biomarkers for immunotherapy plus chemotherapy: Results from phase III RATIONALE-309 and ORIENT-11 randomized trials.Org: Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China, Shantou University Medical College, Shantou, China,
Abstract
Possibilities of long-term atezolizumab immunotherapy in patients with metastatic urothelial cancer.Org: Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Tashkent, Uzbekistan,
Abstract
A phase I clinical study to evaluate the safety, tolerability, immunogenicity, pharmacokinetics and preliminary efficacy of SCB-219M in patients with chemotherapy-induced thrombocytopenia (CIT): An interim analysis.Org: Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, The Sixth People's Hospital of Chengdu,
Abstract
Prognostic analysis of disitamab vedotin combined with PD-1 inhibitor first-line treatment in advanced urothelial carcinoma: A propensity score analysis.Org: Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, The Xiangya Hospital of Central South University,
Abstract
A phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma.Org: Servier Pharmaceuticals LLC,
Abstract
Tislelizumab combined with gemcitabine and cisplatin (GC) as adjuvant therapy in patients with high-risk upper urothelial carcinoma (UTUC) after surgery: A 2-year follow-up, real-world study.Org: Xi’an, China,
Abstract
Developing behavioral intervention to support molecular testing of patients with biliary tract cancer.Org: Georgetown University, Lombardi Comprehensive Cancer Center, Lewis Katz School of Medicine, Center for Discovery & Innovation, Hackensack Meridian Health,
Abstract
Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial.Org: New York University, Grossman School of Medicine, New York University, School of Medicine, Division of Medical Oncology, University of Kansas Medical Center, Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,
Abstract
Genomic and biomarker analysis of immunotherapy combined with chemotherapy treated for patients with metastatic BTC cancer: A real world study.Org: Chinese People's Liberation Army General Hospital, Chinese People’s Liberation Army General Hospital, Senior Department of Oncology, The 5th Medical Center of the PLA General Hospital,
Abstract
Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39.Org: University of California Irvine Medical Center, Santa Creu i Sant Pau Hospital, Seattle Cancer Care Alliance, IDIVAL, Barts Cancer Centre QMUL,
Abstract
Durvalumab plus gemcitabine/cisplatin/nab-paclitaxel in resectable biliary tract cancer: A phase II, single-arm, open-label study (DurGAP).Org: Department of Hepatobiliary and Pancreatic Oncology, Tianjin Cancer Hospital Airport Hospital, Tianjin, China,
Abstract
Randomized phase II/III trial of gemcitabine plus nab-paclitaxel versus concurrent chemoradiotherapy with S-1 as neoadjuvant treatment for borderline resectable pancreatic cancer: GABARNANCE study.Org: The University of Tokyo, Tokyo, Japan, National Cancer Center Hospital Japan East, Kashiwa, Japan, Sapporo Medical University Hospital, Sapporo-Shi, Japan, Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, Shizuoka Cancer Center, Nagaizumi, Japan,
Abstract
Maintenance therapy with avelumab as the first-line treatment in patients with metastatic urothelial carcinoma: A real-world, ambispective RAVE-Bladder study.Org: Moscow City Oncological Hospital No.1, Krasnoyarsk Regional Clinical Oncological Dispensary Named After A.I. Kryzhanovsky, Clinical hospital #1, Medsi Otradnoe, SBHI Leningrad Regional Clinical Hospital,
Abstract
Epidemiology, survival and new treatment modalities for intrahepatic cholangiocarcinoma (IHCC).Org: Ascension Providence Hospital, Ascension Providence/MSUCHM Program, Newland Medical Associates, P.C.,
Abstract
First-line (1L) systemic therapy in locally advanced/metastatic urothelial cancer (Ia/mUC): A living interactive systematic review and network meta-analysis.Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Division of Hematology and Medical Oncology, Mayo Clinic, Phoeniz, AZ,
Abstract
Gemcitabine and cisplatin chemotherapy plus penpulimab combined with or without anlotinib as neoadjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A prospective, phase II clinical trial.Org: Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center,
Abstract
Economic evaluation of the novel PD-1 inhibitor toripalimab in recurrent or metastatic nasopharyngeal carcinoma: Cost-efficiency and expanded access modeling versus pembrolizumab.Org: Matrix45 LLC,
Abstract
Predictive value of baseline 68Ga‑FAPI PET/CT in the first-line therapy of pancreatic ductal adenocarcinoma (PDAC).Org: Senior Department of Oncology, The 5th Medical Center of the PLA General Hospital, Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Chinese Academy of Medical Sciences and Peking Union Medical College,
Abstract
Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial): Interim analysis.Org: Dept of Oncology, Research Institute and Hospital, National Cancer Center, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, Nucleus Network,
Abstract
Envafolimab combined with lenvatinib and gemcitabine plus cisplatin in advanced biliary tract cancer as first-line treatment: A single-arm, open-label, phase II study (ENLIGHTEN study).Org: First People’s Hospital of Foshan, Foshan First People's Hospital,
Abstract
Effect of patient-derived tumor-like cell clusters on personalized medicine of patients with non-muscle invasive bladder cancer.Org: College of Future Technology Peking University, Peking University People’s Hospital, Beijing, China,
Abstract
Patient-derived 3D bioprinting pan-cancer drug screening platform for personalized medicine.Org: Department of Liver Surgery, Peking Union Medical College Hospital, Beijing, China, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, Department of Physiology, Institute of Basic Medical Sciences, CAMS, Beijing, China, Department of Neurosurgery, Peking Union Medical College Hospital, Beijing, China, Department of Head and Neck Surgical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China,
Abstract
Real-world effectiveness and safety of PD-1 inhibitors combined with recombinant human endostatin and chemotherapy in refractory, recurrent/metastatic nasopharyngeal carcinoma.Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou Yirui Pharmaceutical Technology,
Abstract
Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with resectable pancreatic ductal adenocarcinoma.Org: Cancer Research Center of Marseille (CRCM), Digestive and Medical Oncology Department, Paul Brousse Hospital, Cancer Centre of Southeastern Ontario/Queen's University, Paoli-Calmettes Institute,
Abstract
First-line treatment patterns among patients with metastatic pancreatic ductal adenocarcinoma in the real-world setting.Org: Ipsen Biopharmaceuticals,
Abstract
First results of the NOGGO PERCEPTION: Phase II investigational study of pembrolizumab in combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer.Org: North-Eastern German Society of Gynaecological Oncology (NOGGO), Department of Gynecology with Center for Oncological Surgery, Charité-University Medicine of Berlin, Campus Virchow Klinikum, Berlin, Germany, North-Eastern-German Society of Gynaecological Oncology, Berlin, Germany, Kliniken Essen-Mitte, Department of Gynecology and Gynecological Oncology, Essen, Germany, Charité Universitätsmedizin Berlin and North Eastern German Society for Gynecologic Oncology (NOGGO), Berlin, Germany,
Abstract
Tislelizumab in combination with GEMOX and lenvatinib for conversion therapy of unresectable extrahepatic biliary tract carcinoma (eBTC): A prospective, single-arm, phase 2 study.Org: Department of Organ transplantation, the Third Medical Center of Chinese People’s Liberation Army (PLA) General Hospital, Faculty of Hepatopancreatobiliary Surgery, the First Medical Center of Chinese People’s Liberation Army (PLA) General Hospital,
Abstract
Lenvatinib, gemcitabine, and oxaliplatin for 67 patients with fibrolamellar carcinoma.Org: FibroFighters Foundation, NY Presbyterian, St. George Hospital, Helen DeVos Children’s Hospital,
Abstract
Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis.Org: Gregorio Marañón University General Hospital, IRCCS Istituto Romagnolo per lo Studio dei Tumori, Institute of Oncology Ljubljana, Roche Products Limited, Roche,
Abstract
Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC).Org: Asan Medical Center, University of California Los Angeles, University of California Irvine, Hannover Medical School, Zhongshan Hospital,
Abstract
Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial.Org: Memorial Sloan Kettering Cancer Center, Azienda Ospedaliera Universitaria Integrata di Verona, Hospital Universitario Miguel Servet, Centre Léon Bérard, Masaryk Memorial Cancer Institute,
Abstract
Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial.Org: Sun Yat-sen University Cancer Center, Clinical Research Design Division, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Nanfang Hospital, Sun Yat-sen Memorial Hospital,
Abstract
PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM).Org: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Guizhou Cancer Hospital, Guiyang, China, Affiliated Tumor Hospital of Guangxi Medical University, Guangxi, China, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Xijing Hospital, Xi'an, China,
Abstract
Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.Org: Dana-Farber Cancer Institute, Mayo Clinic, Harvard Medical School, Brigham and Women's Hospital/Massachusetts General Hospital, National Cancer Institute, Vilnius, Lithuania,
Abstract
NEOSPACE trial: Neoadjuvant pembrolizumab-gemcitabine-cisplatin followed by concurrent pembrolizumab-chemoradiation and maintenance pembrolizumab for stage IVA nasopharyngeal cancer (NPC).Org: Department of Clinical Oncology, Prince of Wales Hospital, Shatin, Hong Kong, National Cancer Center of Singapore, Singapore, Department of Chemical Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong, Department of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Shatin, Hong Kong, Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong,
Abstract
Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC).Org: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, Cabrini Research, Malvern, Australia, University Clinical Center of Republic of Srpska, Banja Luka, Bosnia and Herzegovina, Linear Cancer Research and University of Western Australia, Nedlands, Western Australia, Australia,
Abstract
A multicenter, open-label, randomized phase II study evaluating adjuvant gemcitabine plus cisplatin (GC) and capecitabine with concurrent capecitabine radiotherapy (CAPE-RT) in patients with operated gallbladder adenocarcinoma (GBC): The GECCOR-GB trial.Org: Tata Memorial Hospital (HBNI), HBNI, HBNI University, Homi Bhabha cancer hospital and research centre, Homi Bhabha Cancer Hospital &Research Centre,
Abstract
Phase 2 trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder.Org: Columbia University Irving Medical Center, New York, NY, USA, Columbia University Vagelos College of Physicians and Surgeons, Columbia University - Mailman School of Public Health,
Abstract
Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC).Org: University of California, San Francisco, Division of Endocrinology, San Francisco, CA, University of California San Francisco, UCSF Medical Center, Helen Diller Family Comprehensive Cancer Center, University of California Comprehensive Cancer Center,
Abstract
Pilot study of a micro-organosphere drug screen platform to lead care in advanced breast cancer (MODEL-ABC).Org: Xilis, Duke University Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Xilis, Inc., Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
A phase 2 randomized, open-label, multicentre study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC.Org: Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Chinese Academy of Sciences,
Abstract
KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen.Org: Caris Life Sciences, Irving, TX, Hoag Memor Hosp, Barbara Ann Karmanos Cancer Institute, Dana-Farber Cancer Institute, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ,
Abstract
An intelligent machine learning model for real-time early detection of undesirable cancer events: AIM2REDUCE.Org: Princess Margaret Cancer Centre, Department of Computer Science, University of Toronto,
Abstract
Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors.Org: University of Washington/Fred Hutchinson Cancer Research Center, University of California, San Francisco, Division of Endocrinology, San Francisco, CA, Sarah Cannon Research Institute at HealthONE, University of Michigan Rogel Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors.Org: National Taiwan University Hospital Yunlin Branch, Taipei Veterans General Hospital, National Cheng Kung University Hospital, China Medical University Hospital, National Institute of Cancer Research, National Health Research Institutes,
Abstract
Survival outcomes in patients with muscle-invasive bladder cancer receiving neoadjuvant chemotherapy stratified by number of cycles.Org: Temple University Health System, Fox Chase Cancer Center, Temple Health,
Abstract
Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.Org: American University of Beirut Medical Center, National Cancer Centre of Singapore, Acıbadem Research Institute of Senology, Medical Oncology, Seoul National University Hospital, Independent Patient Advocate,
Abstract
Outcomes by complete response to first-line pembrolizumab or platinum-based chemotherapy in advanced urothelial carcinoma (UC) in KEYNOTE-361.Org: Adana Baskent Üniversitesi, Adelaide and Meath Hospital, University College Dublin, Instituto Valenciano de Oncología, Ivanovo Regional Oncology Dispensary,
Abstract
BOLD-100-001 (TRIO039): A phase 1b/2a study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pre-treated advanced gastric and biliary tract cancer: Efficacy and safety analysis.Org: Trinity St. James’s Cancer Institute, Cross Cancer Institute, Seoul National University Hospital, Yonsei Cancer Center, Yonsei University Health System, Princess Margaret Cancer Centre,
Abstract
A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer.Org: USF Health Morsani College of Medicine, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center - Fellowship (GME Office), Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, MSKCC,
Abstract
Randomized phase 2 study of maintenance olaparib vs olaparib plus durvalumab for DNA damage repair (DDR) gene mutated unresectable or metastatic biliary tract cancer (BTC) with durable response to first-line platinum-based chemotherapy: OPTIMUM trial.Org: Clinical Trial Center and Department of Epidemiology - IRCCS Ospedale Policlinico San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
A phase Ib trial of the VEGF fusion protein HB002.1T plus chemotherapy in patients with advanced solid tumors.Org: Huaota Biopharma Co., Ltd., Shanghai, China, Huaota Biopharm Co., Ltd., Shanghai, China, Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences,
Abstract
Randomized phase 2 study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in patients with advanced pancreatic cancer (PACTO).Org: Copenhagen University Hospital - Herlev and Gentofte, Oslo University Hospital, Division of Cancer Medicine, Oslo, Norway, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN,
Abstract
Phase 1b/2 trial of pepinemab plus avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma.Org: University of Rochester Cancer Center & Wilmot Cancer Institute, Vaccinex, Inc., University of North Carolina at Chapel Hill,
Abstract
Ex-vivo analysis of programmed cell death on fibrolamellar carcinoma.Org: Rush University Medical School, FibroFighters Foundation, Nagourney Cancer Institute, FibroFighters.org, Rush University Medical Center,
Abstract
Final analysis results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy in patients with cT2-T4aN0M0 MIBC.Org: Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan, China, Department of Urology, The Second Hospital of Anhui Medical University, Hefei, China, Department of Urology, Peking University People's Hospital, Beijing, China,
Abstract
Response-adapted therapy for locally advanced nasopharyngeal carcinoma based on clinical response and circulating Epstein-Barr virus DNA level post induction chemotherapy.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Fudan University Shanghai Cancer Center,
Abstract
Ex vivo tumor testing platform for predicting clinical response to platinum-based therapy in patients with high grade serous ovarian cancer.Org: Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands Cancer Institute, Leiden University Medical Center, Leiden University,
Abstract
A phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel, and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).Org: Senior Department of Oncology, the 5th Medical Center of the PLA General Hospital, Beijing, China, Medical Affairs Department, 3D Medicines, Shanghai, China,
Abstract
Utility of circulating tumor DNA (ctDNA) as a predictive biomarker for disease monitoring in patients (pts) with cholangiocarcinoma (CCA) before and during adjuvant chemotherapy (ACT): Sub-analysis of the randomized phase 2 STAMP trial.Org: Natera, Inc., Asan Medical Center, University of Ulsan College of Medicine, Digestive Disease Research Center,
Abstract
Economic evaluation for the US of durvalumab plus gemcitabine and cisplatin (DGC) in advanced biliary tract cancer (BTC).Org: Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, University of Arizona of Pharmacy, Department of Pharmacy Practice and Science,
Abstract
Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).Org: Sun Yat-sen University Cancer Center Gansu Hospital, The Affiliated Cancer Hospital of Guangzhou Medical University, Fudan University Cancer Center, Cancer Center Union Hospital Tongji Medical College Huazhong University of Science and Technology, Affiliated Hospital of Guangdong Medical University,
Abstract
ALTER-UC-007: A prospective phase 2 study of anlotinib with gemcitabine and cisplatin or anlotinib with penpulimab as perioperative treatment for patients with muscle-invasive urothelial carcinoma (MIUC).Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Fudan University Shanghai Cancer Center, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
The safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: Preclinical mouse model and phase I/IIa clinical study.Org: C&SR Inc., NKMAX Co., Ltd., NKGen Biotech Inc.,
Abstract
Early experience with nivolumab, gemcitabine, and lenvatinib for fibrolamellar hepatocellular carcinoma.Org: FibroFighters Foundation, River Forest, IL, Rush University Medical Center, Chicago, IL, University of Zürich,
Abstract
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).Org: Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany, Bruederkrankenhaus St. Josef Paderborn, Technical University Munich, Universitätsklinikum Freiburg Klinik Für Innere Medizin II Gastrointestinale Onkologie, Onkologische und Hamatologische Schwerpunktpraxis,
Abstract
Safety and clinical activity of oleclumab (O) ± durvalumab (D) + chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A phase 1b/2 randomized study.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, University of Michigan Health System Comprehensive Cancer Center, Hospital Universitari Vall d'Hebron Research Institute, Roswell Park Cancer Institute,
Abstract
A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.Org: Memorial Sloan Kettering Cancer Center, University of Kansas Medical Center Department of Internal Medicine, NSABP/NRG Oncology and Wake Forest University Baptist Medical Center, Gettysburg Cancer Center, University of Arizona Cancer Center,
Abstract
A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.Org: SWOG Statistics and Data Management Center, Seattle, WA, University of California Davis Comprehensive Cancer Center, Fred Hutchinson Cancer Research Center, SWOG Cancer Research Network, Baylor College of Medicine,
Abstract
ABC-12: Exploring the microbiome in patients (pts) with advanced biliary tract cancer (BTC) in a first-line study of durvalumab in combination with cisplatin/gemcitabine (cis/gem).Org: University of Manchester/The Christie NHS Foundation Trust, Manchester, United Kingdom, Cardiff University School of Medicine, Cardiff, United Kingdom, The Christie and Salford Royal Hospital NHS Foundation Trusts,
Abstract
A phase 2 study of HMPL-453, a selective FGFR tyrosine kinase inhibitor (TKI), in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions.Org: HUTCHMED Limited, Shanghai, China,
Abstract
Components of total cost of care in real-world patients with mPDAC who received first-line FOLFIRINOX or Gem/Abrax.Org: Milliman, Inc., Ipsen Biopharmaceuticals, Inc., George Washington University Hospital,
Abstract
Gemcitabine, cisplatin, nab-paclitaxel: The effectiveness of this regimen for gall bladder cancer.Org: Tata Memorial Hospital (HBNI), Tata Memorial Centre, Tata Memorial Center (HBNI),
Abstract
A phase II study of toripalimab combined with gemcitabine-cisplatin as neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC).Org: Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, China, Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China,
Abstract
Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer: A multi-center, open-label, single-arm, phase II study.Org: The Fifth Affiliated Hospital of Sun Yet-Sen University, Zhuhai, China, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, Zhuhai Hospital of lntegrated Traditional Chinese and Western Medicine, Zhuhai, China, Department of Breast Surgery, Zhuhai Maternity and Child Health Hospital, Zhuhai, China, The First People's Hospital of Zhaoqing, Zhaoqing, China,
Abstract
A comparative study evaluating the quality of life in patients receiving chemotherapy versus oral TKI in the third line and beyond setting for advanced non–small-cell lung cancer.Org: Tata Memorial Centre, Tata Memorial Hospital (HBNI),
Abstract
Clinicopathological features and treatment profile of patients referred to a sarcoma medical oncology centre in India: Challenges and insights from the developing world.Org: All India Institute of Medical Sciences, Delhi, India, All India Institute of Medical Sciences, New Delhi, India,
Abstract
Real-world clinical outcomes in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US).Org: Dana-Farber Cancer Institute, University Hospitals Leuven, Leuven, Belgium, Stanford University School of Medicine, Gilead Sciences Europe Ltd., Gilead Sciences Inc.,
Abstract
Effects of namodenoson on pancreatic carcinoma: Preclinical evidence.Org: Can-Fite Ltd., BioInsight, Canfite,
Abstract
Biliary intervention combined with lenvatinib+ PD-1 inhibitor of Klatskin tumor complicated with malignant obstructive jaundice.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,
Abstract
Safety and tolerability of HLX07 combined with chemotherapy in patients with advanced solid tumors.Org: Shanghai East Hospital, Tongji University, Shanghai, China, School of Medicine, Zhejiang University, Hangzhou, China, Tongji University School of Medicine, Shanghai Henlius Biotech, Inc.,
Abstract
Effects of the baseline prognostic factors on efficacy of the p62/SQSTM1-encoding plasmid combined with gemcitabine in patients with recurrent platinum-resistant ovarian cancer.Org: CureLab Oncology, Inc., N.N. Alexandrov National Cancer Centre of Belarus, Minsk City Clinical Oncologic Centre, Gynecologic Oncology Group (GOG) and Department of Obstetrics/Gynecology, Perlmutter Cancer Center, NYU Langone Health,
Abstract
Safety of locally administered large surface area microparticle paclitaxel and docetaxel in combination with standard of care cancer therapies.Org: US Biotest,
Abstract
AI-based pathologic biomarker for pathologic downstaging in patients with muscle-invasive bladder cancer undergoing cystectomy after neoadjuvant nivolumab, gemcitabine, and cisplatin: BLAAST-1 Trial.Org: Valar Labs, Inc., Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Huntsman Cancer Institute, Hunstman Cancer Institute at the University of Utah,
Abstract
A single-institution analysis of a rare variant of pancreatic neoplasm-osteoclastic giant cell tumor.Org: University of Nebraska Medical Center, Omaha, NE,
Abstract
Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma.Org: Center for Cancer Research, National Cancer Institute, Biostatistics and Data Management Section, OCD, NCI, NIH, Bethesda, MD, Radiology and Imaging Sciences, CCR, NCI, NIH, Bethesda, MD, Center for Interventional Oncology, Thoracic and GI Oncology Branch,
Abstract
A phase Ib/II, open-label, multicenter study to evaluate the safety, efficacy, and pharmacokinetics/pharmacodynamics of αvβ3/5 integrin and neuropilin-1 targeting peptide LSTA1 in patients with metastatic pancreatic ductal adenocarcinoma.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The Fifth Medical Center of Chinese PLA General Hospital, Department of Gastroenterology and Urology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Harbin Medical University Cancer Hospital,
Abstract
Treatment and outcomes of pancreatic cancer in Armenia: Hospital-based study.Org: Immune Oncology Research Institute, National Center of Oncology named after V.A. Fanarjyan, Hematology center after prof. Yeolyan, Mikaelyan Institute of Surgery, City University of Hong Kong,
Abstract
Neoadjuvant camrelizumab plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A single-arm, phase II trial.Org: The First Affiliated Hospital of University of Science and Technology of China, Hefei, China, Anhui Provincial Cancer Hospital, Hefei, China, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China,
Abstract
Oxaliplatin based chemotherapy for advanced well-differentiated neuroendocrine tumors: A systematic review and meta-analysis.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Qilu Hospital of Shandong University, Jinan, China National Biotec Group,
Abstract
Survival outcomes of liposomal irinotecan in patients with advanced pancreatic adenocarcinoma previously treated with conventional irinotecan-based chemotherapy: A single-institution experience.Org: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Baltimore, MD,
Abstract
Comparison of first-line treatments for recurrent or metastatic nasopharyngeal carcinoma based on phase 3 randomized clinical trials.Org: Department of Radiotherapy, Jiangsu Cancer Hospital, Nanjing, Jiangsu, China, Yunnan Cancer Hospital, Kunming, Yunnan, China, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China, Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine, Durham, NC,
Abstract
Chemotherapy combined with anlotinib, toripalimab and stereotactic radiotherapy in oligo-metastatic nasopharyngeal carcinoma: A prospective, multicenter phase II clinical study.Org: Department of Radiation Oncology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China, Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China, Liuzhou Worker's Hospital, Liuzhou, China,
Abstract
Analysis of the efficacy and safety of PD-1/PD-L1 inhibitors–based treatment in myxofibrosarcoma: A single-institution retrospective analysis.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Tislelizumab (Tisle) combined with/without gemcitabine and cisplatin (GC) as adjuvant therapy in patients at high risk after upper urothelial carcinoma (UTUC) surgery: A real-world study.Org: XIjing Hospital of Air Force Military Medical University, Xi’an, China, Xijing Hospital Fourth Military University, the Air Force Military Medical University, Xiijng Hospital,
Abstract
Comparison of bevacizumab plus doublet chemotherapy regimens in patients with metastatic or recurrent ovarian cancer.Org: Istanbul University Institute of Oncology, Basaksehir Cam and Sakura City Hospital,
Abstract
A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer whose disease progressed on gemcitabine-based therapy.Org: Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, Washington University School of Medicine in St Louis, St. Louis, MO, Washington University School of Medicine in St. Louis, Dartmouth Hitchcock Medical Center,
Abstract
Cost-effective analysis of rotational intraperitoneal aerosol chemotherapy (RIPAC) in patients with platinum-resistant ovarian cancer.Org: Seoul National University Hospital, Seoul National University College of Medicine,
Abstract
Clinical utility of an international multidisciplinary virtual tumor board for fibrolamellar carcinoma.Org: FibroFighters Foundation, Rush University Medical Center, University of Zürich, Columbia University - Mailman School of Public Health, UPMC Health Plan,